Venous Thromboembolism, interventional treatment for Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT).

Venous Thromboembolism

Advancing minimally-invasive, interventional treatment for Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT).

New strategies for treating Venous Thromboembolism

Venous thromboembolism (VTE) is a very common but silent condition in which a blood clot forms in the vein. It manifests itself either as Deep Vein Thrombisis (DVT), which occurs when the clot forms in the deep vein of the leg, groin or arm; or Pulmonary Embolism (PE), when the clot travels in the circulation and advances to the lungs. VTE is a dangerous medical condition and one of the leading causes of death and disability worldwide.

Detailed estimates of VTE events are hard to obtain because they are very difficult to diagnose and often clinically silent. However, VTE is preventable and evidence-based prevention strategies can help stop the development of clots in 'at-risk' individuals.

Boston Scientific seeks to make minimally-invasive, interventional treatments the new standard of care for treating intermediate-high-risk Pulmonary Embolism and DVT.

Help patients with Pulmonary Embolism get better faster, for longer

PE directly causes or contributes to 15% of hospital deaths.1 
Ultrasound-assisted, catheter-based thrombolysis opens new treatment options between anticoagulation and systemic thrombolysis. 

Learning Centre

Visit the Learning Centre to access case studies, expert videos, learning programme overviews, a bibliography of clinical articles and more.

What’s new

New studies, new campaigns, new training modules…Visit What’s new to discover the latest findings and activities in this field.

Pulmonary Embolism and its symptoms


PE patients with evidence of DVT


PE risk if proximal DVT

Pulmonary embolism (PE) usually originates as deep vein thrombosis (DVT) – clot formation in the deep veins of the leg, groin or arm. PE occurs when the clot travels in the circulation and lodges in the lungs. 50% of patients who have proximal DVT (clot in the popliteal, femoral, or iliac veins) are at risk of PE2, and 79% of patients presenting with PE have evidence of DVT.3,4
Learn more about Pulmonary Embolism and its symptoms.

Expand your education about endovascular interventions

Learn about the Boston Scientific blended learning programmes and on-demand training resources available to you in EDUCARE

1. Beers, M.H., et al., The Merck Manual of Diagnosis and Therapy. 18th edition. Whitehouse Station, NJ: Merck Research Laboratories, 2006: 412-22, 427, 2081-2
2. Jha AK, et al. The global burden of unsafe medical care: analytic modeling of observational studies. BMJ Qual Saf 2013; 22;809-15
3. Sandler, D.A., et al., “Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?” J R Soc Med, 1989; 82: 203-5.
4. Huisman, M.V., et al., “Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis.” Chest, 1989; 95(3): 498-502.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.